CN109134595B - 茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 - Google Patents
茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 Download PDFInfo
- Publication number
- CN109134595B CN109134595B CN201710457355.7A CN201710457355A CN109134595B CN 109134595 B CN109134595 B CN 109134595B CN 201710457355 A CN201710457355 A CN 201710457355A CN 109134595 B CN109134595 B CN 109134595B
- Authority
- CN
- China
- Prior art keywords
- methoxyphenyl
- hydroxy
- heptadiene
- residue
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 amino acid benzyl ester modified curcumin Chemical class 0.000 title claims abstract description 37
- 230000000694 effects Effects 0.000 title abstract description 9
- 230000015572 biosynthetic process Effects 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 9
- PZCOGSNWFOZOPG-UHFFFAOYSA-N benzyl 2-(4-formyl-2-methoxyphenoxy)acetate Chemical compound COC1=CC(C=O)=CC=C1OCC(=O)OCC1=CC=CC=C1 PZCOGSNWFOZOPG-UHFFFAOYSA-N 0.000 claims description 7
- 230000004614 tumor growth Effects 0.000 claims description 6
- IMTRYJGZTHQKDH-UHFFFAOYSA-N [2-[7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl]-6-methoxyphenyl] 3,4-dioxobutanoate Chemical compound OC1=C(C=C(C=C1)C=CC(CC(C=CC1=C(C(=CC=C1)OC)OC(CC(=O)C=O)=O)=O)=O)OC IMTRYJGZTHQKDH-UHFFFAOYSA-N 0.000 claims description 5
- DATAGRPVKZEWHA-YFKPBYRVSA-N L-Theanine Natural products CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940026510 theanine Drugs 0.000 claims description 3
- CPQJQZYHUSDAGA-UHFFFAOYSA-N COC(C=C(C=CC(CC(C=CC(C=C1)=C(CC2=CC=CC=C2)C(OC)=C1C(CC(C=O)=O)=O)=O)=O)C=C1)=C1O Chemical compound COC(C=C(C=CC(CC(C=CC(C=C1)=C(CC2=CC=CC=C2)C(OC)=C1C(CC(C=O)=O)=O)=O)=O)C=C1)=C1O CPQJQZYHUSDAGA-UHFFFAOYSA-N 0.000 claims description 2
- 229940125898 compound 5 Drugs 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- QSXDREMICJNZIV-WCSIJFPASA-N CCNC(C(C[C@@H](C(NC1=C(C=CC(CC(C=CC(C=C2)=CC(OC)=C2O)=O)=O)C=CC=C1OC)=O)N)C(C=O)=O)=O Chemical compound CCNC(C(C[C@@H](C(NC1=C(C=CC(CC(C=CC(C=C2)=CC(OC)=C2O)=O)=O)C=CC=C1OC)=O)N)C(C=O)=O)=O QSXDREMICJNZIV-WCSIJFPASA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- JKWMSGQKBLHBQQ-UHFFFAOYSA-N diboron trioxide Chemical compound O=BOB=O JKWMSGQKBLHBQQ-UHFFFAOYSA-N 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical class C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 4
- LGQXXHMEBUOXRP-UHFFFAOYSA-N tributyl borate Chemical compound CCCCOB(OCCCC)OCCCC LGQXXHMEBUOXRP-UHFFFAOYSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- QSIUEBXEXBQDDI-UHFFFAOYSA-N OC1=C(C=C(C=C1)C=CC(CC(C=CC1=C(C(=CC=C1)OC)C(=O)OCC1=CC=C(C=C1)C(C=O)=O)=O)=O)OC Chemical compound OC1=C(C=C(C=C1)C=CC(CC(C=CC1=C(C(=CC=C1)OC)C(=O)OCC1=CC=C(C=C1)C(C=O)=O)=O)=O)OC QSIUEBXEXBQDDI-UHFFFAOYSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- FQIOJDQAGANVPK-UHFFFAOYSA-N COC=1C=C(C=CC=1O)C=CC(CC(C=CC1=CC(=C(C=C1)OC(C=O)=O)OC)=O)=O Chemical compound COC=1C=C(C=CC=1O)C=CC(CC(C=CC1=CC(=C(C=C1)OC(C=O)=O)OC)=O)=O FQIOJDQAGANVPK-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 2
- 229910052810 boron oxide Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical class [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
- TZAXXVOCHPBIBY-UHFFFAOYSA-N OC1=C(C=C(C=C1)C=CC(CC(C=CC1=C(C(=CC=C1)OC)OCC1=CC=C(C=C1)C(C=O)=O)=O)=O)OC Chemical compound OC1=C(C=C(C=C1)C=CC(CC(C=CC1=C(C(=CC=C1)OC)OCC1=CC=C(C=C1)C(C=O)=O)=O)=O)OC TZAXXVOCHPBIBY-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- TYQYRKDGHAPZRF-INIZCTEOSA-N benzyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)OCC1=CC=CC=C1 TYQYRKDGHAPZRF-INIZCTEOSA-N 0.000 description 1
- MBRRYUQWSOODEO-LBPRGKRZSA-N benzyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OCC1=CC=CC=C1 MBRRYUQWSOODEO-LBPRGKRZSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
技术领域
本发明涉及1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-AA-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮,涉及它们的制备方法,涉及它们的抗肿瘤生长活性,因而本发明涉及它们在制备抗肿瘤药物中的应用。本发明属于生物医药领域。
背景技术
恶性肿瘤是严重危害人类健康的全球性问题。肿瘤患者发现病患时大多已是临床中晚期,治疗方法以放化疗为主,化疗是恶性肿瘤处于中晚期时的主要治疗手段。发明抗肿瘤药物是临床的迫切需求。此前,发明人曾公开1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰氨基酸苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮具有明显的抑制肿瘤细胞增殖的活性。后来发明人又公开抗黏附肽修饰的姜黄素在1μmol/kg剂量下可抑制S180小鼠肿瘤生长。可是最低有效剂量为1μmol/kg。为了降低最低有效剂量,发明人对姜黄素的酚羟基展开了各种修饰。经过3年探索,发现用茶氨酰-AA-OBzl(AA选自L-Ala残基、L-Gly残基、L-Leu残基、L-Arg残基、L-Trp残基和L-Tyr残基)修饰姜黄素可使抗肿瘤的最低有效剂量降至0.1μmol/kg。有效剂量降低10倍表明,这种结构修饰有突出的技术效果。根据这些发现,发明人提出了本发明。
发明内容
本发明的第一个内容是提供下式所示的1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-AA-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(式中AA选自L-Ala残基、L-Gly残基、L-Leu残基、L-Arg残基、L-Trp残基和L-Tyr残基)。
本发明的第二个内容是提供1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-AA-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(AA选自L-Ala残基、L-Gly残基、L-Leu残基、L-Arg残基、L-Trp残基和L-Tyr残基)的合成方法,该方法包括:
(1)制备6-(4-羟基-3-甲氧苯基)-5,6-己烯-2,4-二酮(1);
(2)制备2-(4-甲酰基-2-甲氧基苯氧基)-乙酸苄酯(2);
(3)以步骤(1)和步骤(2)的产物为反应原料制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(3);
(4)将1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮皂化,得到1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰乙酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(4);
(5)化合物4和L-茶氨酸苄酯偶联得到1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(5);
(6)将化合物5皂化得到1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(6);
(7)化合物6和L-氨基酸苄酯偶联得到1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-AA-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮。
本发明的第三个内容是评价1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-AA-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮对S180小鼠肿瘤生长的抑制应用。
附图说明
图1为1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-AA-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮.7a中AA为L-Ala残基;7b中AA为L-Gly残基;7c中AA为L-Leu残基;7d中AA为L-Arg残基;7e中AA为L-Trp残基;7f中AA为L-Tyr残基;i)三氧化二硼(B2O3),乙酰丙酮,硼酸三正丁酯,正丁胺,氯化氢水溶液(1M);ii)碳酸钾,溴乙酸苄酯;iii)三氧化二硼(B2O3),硼酸三正丁酯,正丁胺,10%乙酸水溶液;iv)氢氧化钠水溶液(2M),丙酮;v)二环己基碳二亚胺(DCC),1-羟基苯并三唑(HOBt),N-甲基吗啉(NMM),四氢呋喃(THF)。
具体实施方式
为了进一步阐述本发明,下面给出一系列实施例。这些实施例完全是例证性的,它们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。
实施例1制备6-(4-羟基-3-甲氧苯基)-5,6-己烯-2,4-二酮(1)
将45.0mL(437.7mmol)乙酰丙酮,21.0g(301.6mmol)氧化硼和150.0mL无水乙酸乙酯于60℃回流1h。然后,往里加22.5g(148.0mmol)香草醛和41mL(293.0mmol)硼酸三丁酯。反应混合物70℃搅拌30min。于30min内继续往里加15mL(205.1mmol)正丁胺与135mL乙酸乙酯中的溶液。混合物于100℃搅拌3h后冷却至室温,并往里滴加150mL盐酸(1M)。混合物于50℃搅拌30min,静置,充分分层,水层用乙酸乙酯萃取3次。合并的乙酸乙酯层用饱和NaCl溶液洗至中性,无水硫酸钠干燥,过滤,滤液减压浓缩至干,残留物用硅胶柱层析纯化(石油醚/乙酸乙酯=4/1)得到10.05g(29%)目标化合物,为黄色固体。ESI-MS(m/e):235[M+H]+;1H NMR(300MHz,DMSO-d6):δ/ppm=15.74(s,1H),9.64(s,1H),7.50(d,J=15.9Hz,1H),7.30(s,1H),7.12(d,J=8.1Hz,1H),6.82(d,J=8.1Hz,1H),6.64(d,J=15.9Hz,1H),5.84(s,1H),5.14(s,2H),3.83(s,3H),2.12(s,3H)。
实施例2制备3-甲氧基-4-(氧基-2-乙酰苄酯基)苯甲醛(2)
将10g(65.8mmol)香草醛溶于100mL无水四氢呋喃。向该溶液分批加入10.9g(79.0mmol)碳酸钾并搅拌3h。然后向溶液中滴加9.3mL溴乙酸苄酯,室温搅拌48h,TLC监(石油醚/乙酸乙酯=3/1)显示反应结束。反应混合物过滤,滤液减压浓缩,残余物用100mL乙醚磨洗静置12h后倒掉乙醚,10mL乙醚磨洗3次,去乙醚,得到15.4g(78%)标题化合物,为无色固体。ESI-MS(m/e):301[M+H]+;1H NMR(300MHz,DMSO-d6):δ/ppm=9.86(s,1H),7.50(dd,J1=8.4Hz,J2=1.8Hz,1H),7.44(d,J=1.8Hz,1H),7.39(s,5H),7.11(d,J=8.4Hz,1H),5.21(s,2H),5.03(s,2H),3.84(s,3H)。
实施例3制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(3)
将5.55g(23.7mmol)6-(4-羟基-3-甲氧苯基)-5,6-己烯-2,4-二酮(1),0.83g(11.9mmol)氧化硼和100mL乙酸乙酯的悬浮液于70℃回流1h。之后,减压浓缩。残留物用100mL无水DMF溶解。往得到的溶液中加10.67g(35.6mmol)3-甲氧基-4-(氧基-2-乙酰苄酯基)苯甲醛(2)和11.15mL(41.0mmol)硼酸三丁酯。得到的溶液于80℃搅拌30min。之后,往里分4次滴加0.98mL(6.4mmol)正丁胺,用时1h,得到的溶液于80℃继续搅拌3h。之后,往里加200mL预热至60℃的10%乙酸水溶液。得到的溶液于80℃继续搅拌1h。反应混合物冷却至室温,过滤,滤饼用柱层析纯化(石油醚/乙酸乙酯=3/1),得到6.63g(53%)标题化合物,为黄色固体。ESI-MS(m/e):517[M+H]+;1H NMR(300MHz,DMSO-d6):δ/ppm=9.69(s,1H),8.51(d,J=7.5Hz,1H),7.80(t,J=5.7Hz,1H),7.59(d,J=3.0Hz,1H),7.54(d,J=3.0Hz,1H),7.37(m,7H),7.16(m,1H),6.89(m,4H),6.09(s,1H),5.14(s,2H),4.62(s,2H),4.37(m,1H),3.87(s,3H),3.84(s,3H),3.04(qd,J1=7.2Hz,J2=5.7Hz,2H),2.15(m,2H),2.05(m,1H),1.90(m,1H),0.98(t,J=7.2Hz,3H)。
实施例4制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(4)
将5g(9.7mmol)1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(3)用丙酮溶解。室温下往里加NaOH水溶液(2M),调节反应液pH为13并搅拌6h。TLC(石油醚/乙酸乙酯=3/1)显示反应完成。反应混合物用饱和KHSO4水溶液将pH调到7,减压浓缩,残余物用饱和KHSO4水溶液调pH到2。之后,用乙酸乙酯萃取3次。合并乙酸乙酯层,用饱和NaCl溶液洗至中性,用无水硫酸钠干燥。过滤,滤液减压浓缩,残留物用无水乙醚磨洗,得到2.64g(64%)标题化合物,为红色固体。ESI-MS(m/e):425[M-H]-;1H NMR(300MHz,DMSO-d6):δ/ppm=9.55(s,1H),7.57(m,2H),7.37(m,2H),7.20(m,2H),6.79(m,4H),6.06(s,1H),4.74(s,2H),3.85(s,6H)。
实施例5制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(5)
冰浴下将2g(4.7mmol)1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(4),1.69g(5.6mmol)盐酸茶氨酸苄酯和0.761g(5.64mmol)N-羟基苯并三唑(HOBt)用50mL无水四氢呋喃溶解。向溶液中滴入由1.16g(5.63mmol)二环己基羰二亚胺(DCC)和10mL无水四氢呋喃的溶液。反应液用N-甲基吗啉调pH到8,室温搅拌12h。TLC(石油醚/乙酸乙酯=3/1)显示反应完成。反应液减压浓缩至干,残余物用150mL乙酸乙酯溶解。过滤、滤液依次用饱和碳酸氢钠水溶液洗3次,饱和氯化钠水溶液洗3次,饱和硫酸氢钾水溶液洗3次,饱和氯化钠水溶液洗3次,饱和碳酸氢钠水溶液洗3次及饱和氯化钠水溶液洗3次。合并的乙酸乙酯层用无水硫酸钠干燥,过滤,滤液减压浓缩。残留物用柱层析(二氯甲烷/甲醇=80/1)纯化,得到2.24g(71%)标题化合物,为黄色固体。ESI-MS(m/e):673[M+H]+;1HNMR(300MHz,DMSO-d6):δ/ppm=9.69(s,1H),8.51(d,J=7.5Hz,1H),7.80(t,J=5.7Hz,1H),7.59(d,J=3.0Hz,1H),7.54(d,J=3.0Hz,1H),7.37(m,7H),7.16(m,1H),6.89(m,4H),6.09(s,1H),5.14(s,2H),4.62(s,2H),4.37(m,1H),3.87(s,3H),3.84(s,3H),3.04(qd,J1=7.2Hz,J2=5.7Hz,2H),2.15(m,2H),2.05(m,1H),1.90(m,1H),0.98(t,J=7.2Hz,3H)。
实施例6制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(6)
将2.24g(3.3mmol)1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(5)用丙酮溶解,室温下向溶液中滴加NaOH水溶液(2M)至反应液pH为13,搅拌6h,TLC(石油醚/乙酸乙酯=3/1)显示反应完成。用饱和KHSO4水溶液将反应液pH调到7,减压浓缩,残余物用饱和KHSO4水溶液调pH到2。之后,用乙酸乙酯萃取3次,合并的乙酸乙酯层用饱和NaCl水溶液洗至中性,用无水硫酸钠干燥,过滤,滤液减压浓缩得到1.07g(55%)标题化合物,为红色糖浆。ESI-MS(m/e):581[M-H]-;1H NMR(300MHz,DMSO-d6):δ/ppm=9.42(s,1H),8.1(m,1H),7.77(m,1H),7.57(m,1H),7.37(m,1H),7.24(m,2H),7.10(m,2H),6.96(d,J=5.1Hz,1H),6.79(m,3H),6.06(s,1H),4.57(s,2H),4.20(m,1H),3.82(s,6H),3.01(m,2H),2.09(m,3H),1.77(m,1H),0.95(t,J=4.5Hz,3H)。
实施例7制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-Ala-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(7a)
冰浴下将2.83g(6.32mmol)1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(6),1.63g(7.58mmol)HCl·Ala-OBzl和1.02g(7.58mmol)N-羟基苯并三唑(HOBt)用30mL无水四氢呋喃溶解。之后,往里滴加1.56g(7.58mmol)二环己基羰二亚胺(DCC)和10mL无水四氢呋喃的溶液。反应液用N-甲基吗啉(NMM)调pH为8,室温搅拌12h,TLC(二氯甲烷/甲醇=60/1)显示反应结束。反应液减压浓缩至干,残余物用150mL二氯甲烷溶解,抽滤、滤液依次用饱和碳酸氢钠水溶液洗3次,饱和氯化钠水溶液洗3次,饱和硫酸氢钾水溶液洗3次,饱和氯化钠水溶液洗3次,饱和碳酸氢钠水溶液洗3次及饱和氯化钠水溶液洗3次。合并的二氯甲烷层用无水硫酸钠干燥,过滤,滤液减压浓缩至干。残留物用柱层析纯化(二氯甲烷/甲醇=60/1),得到1.64g(35%)标题化合物,为黄色固体。Mp 152-153℃; (c=0.1,甲醇);ESI-MS(m/e):744[M+H]+;IR(cm-1):3284,3068,2973,2931,2851,1736,1641,1626,1584,1540,1508,1449,1374,1337,1267,1211,1135,1030,964,696;1HNMR(300MHz,DMSO-d6):δ/ppm=9.70(s,1H),8.59(d,J=6.9Hz,1H),8.1(d,J=7.8Hz,1H),7.77(t,J=6.0Hz,1H),7.57(d,J=15.6Hz,2H),7.37(m,7H),7.24(d,J=8.1Hz,1H),7.17(d,J=8.1Hz,1H),6.97(d,J=8.4Hz,1H),6.89(m,3H),6.10(s,1H),5.13(s,2H),4.61(s,2H),4.37(m,2H),3.87(s,3H),3.84(s,3H),3.04(qd,J1=7.2Hz,J2=6.0Hz,2H),2.09(m,2H),1.95(m,1H),1.77(m,1H),1.31(d,J=7.2Hz,3H),0.99(t,J=7.2Hz,3H)。
实施例8制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-Gly-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(7b)
采用实例7的方法,从0.17g(0.29mmol)1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(6)和0.12g(0.60mmol)HCl·Gly-OBzl得到65mg(31%)标题化合物,为黄色固体。Mp 208-209℃;(c=0.1,甲醇);ESI-MS(m/e):730[M+H]+;IR(cm-1):3438,3287,3088,2934,1657,1639,1585,1550,1508,1455,1423,1382,1262,1214,1175,1134,1060,1032,962,753,697;1H NMR(300MHz,DMSO-d6):δ/ppm=9.69(s,1H),8.55(t,J=3.6Hz,1H),8.14(d,J=4.8Hz,1H),7.76(t,J=3.3Hz,1H),7.55(d,J=9.3Hz,2H),7.35(m,7H),7.20(d,J=5.10Hz,1H),7.13(d,J=5.1Hz,1H),6.94(d,J=4.8Hz,1H),6.79(m,3H),6.06(s,1H),5.11(s,2H),4.59(s,2H),4.35(m,1H),3.90(dd,J1=7.2Hz,J2=5.7Hz,2H),3.84(s,3H),3.82(s,3H),3.01(qd,J1=6.9Hz,J2=3.3Hz,2H),2.07(t,J=4.8Hz,2H),1.91(m,1H),1.75(m,1H),0.94(t,J=6.9Hz,3H)。
实施例9制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-Leu-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(7c)
采用实施例7的方法,从3.04g(5.22mmol)1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(6)和1.61g(6.26mmol)HCl·Leu-OBzl得到0.93g(23%)标题化合物,为黄色固体。Mp 135-136℃;(c=0.1,甲醇);ESI-MS(m/e):786[M+H]+;IR(cm-1):3282,3068,2958,2934,2872,1738,1629,1585,1541,1507,1449,1370,1339,1252,1215,1125,1030,963,844,696;1H NMR(300MHz,DMSO-d6):δ/ppm=9.71(s,1H),8.50(d,J=6.6Hz,1H),8.09(d,J=5.2Hz,1H),7.78(t,J=6.0Hz,1H),7.57(m,2H),7.36(m,7H),7.22(d,J=7.80Hz,1H),7.17(d,J=8.1Hz,1H),6.96(d,J=8.4Hz,1H),6.81(m,3H),6.09(s,1H),5.13(s,2H),4.61(s,2H),4.37(m,2H),3.87(s,3H),3.84(s,3H),3.04(qd,J1=6.9Hz,J2=6.0Hz,2H),2.28(m,1H),2.08(m,2H),1.92(m,1H),1.77(m,1H),1.58(m,2H),0.99(t,J=6.9Hz,3H),0.87(d,J=5.7Hz,3H),0.82(d,J=5.4Hz,3H)。
实施例10制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨-Arg(NO2)-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(7d)
采用实施例7的方法,从2.5g(5.87mmol)1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(6)和4.33g(8.80mmol)HCl·Arg(NO2)-OBzl得到1.45g(29%)标题化合物,为黄色固体。Mp 162-164℃;(c=0.1,甲醇);ESI-MS(m/e):874[M+H]+;IR(cm-1):3287,2936,1735,1649,1628,1587,1509,1426,1375,1341,1254,1137,1059,1032,962,697;1H NMR(300MHz,DMSO-d6):δ/ppm=9.70(s,1H),8.55(d,J=7.2Hz,1H),8.10(d,J=8.1Hz,1H),7.76(t,J=5.1Hz,1H),7.57(m,2H),7.37(m,7H),7.24(d,J=8.1Hz,1H),7.17(d,J=7.8Hz,1H),6.97(d,J=8.4Hz,1H),6.79(m,3H),6.09(s,1H),5.14(s,2H),4.61(s,2H),4.37(m,2H),3.87(s,3H),3.84(s,3H),3.14(m,2H),3.04(qd,J1=7.2Hz,J2=5.1Hz,2H),2.09(m,2H),1.95~1.53(m,10H),0.99(t,J=7.2Hz,3H)。
实施例11制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-Trp-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(7e)
采用实施例7的方法,从1.97g(3.38mmol)1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(6)和1.12g(3.39mmol)HCl·Trp-OBzl得到1.78g(61%)标题化合物,为黄色固体。Mp 158-159℃;(c=0.1,甲醇);ESI-MS(m/e):858[M+H]+;IR(cm-1):3286,3060,2934,1731,1640,1584,1509,1455,1377,1338,1257,1165,1134,1030,964,845,734,696;1H NMR(300MHz,DMSO-d6):δ/ppm=10.88(s,1H),9.70(s,1H),8.60(d,J=7.2Hz,1H),8.04(d,J=8.1Hz,1H),7.74(t,J=5.4Hz,1H),7.57(m,2H),7.49(d,J=7.8Hz,1H),7.37(m,6H),7.19(m,5H),7.04(m,3H),6.89(m,3H),6.10(s,1H),5.02(m,2H),4.61(m,3H),4.37(m,1H),3.87(s,3H),3.84(s,3H),3.04(m,4H),2.09(m,2H),1.95(m,1H),1.77(m,1H),0.99(t,J=7.2Hz,3H)。
实施例12制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-Tyr-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(7f)
采用实施例7的方法,从2.5g(5.87mmol)1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(6)和3.84g(8.80mmol)HCl·Tyr-OBzl得到1.78g(20%)标题化合物,为黄色固体。Mp 148-150℃;(c=0.1,甲醇);ESI-MS(m/e):836[M+H]+;IR(cm-1):3281,3077,2928,1629,1586,1543,1508,1448,1375,1340,1252,1221,1165,1134,1029,963,810,695;1H NMR(300MHz,DMSO-d6):δ/ppm=9.70(s,1H),9.24(s,1H),8.53(d,J=6.9Hz,1H),8.02(d,J=8.1Hz,1H),7.74(t,J=4.8Hz,1H),7.57(m,2H),7.22(m,9H),7.04(m,3H),6.84(m,3H),6.65(d,J=8.4Hz,2H),6.09(s,1H),5.07(d,J=1.5Hz,2H),4.59(s,2H),4.44(m,2H),3.87(s,3H),3.85(s,3H),3.04(qd,J1=7.2Hz,J2=4.8Hz,2H),2.90(m,2H),2.09(m,2H),1.95(m,1H),1.77(m,1H),0.99(t,J=7.2Hz,3H)。
实施例13测定化合物7a-f的抗肿瘤生长活性
测定前将阿霉素,化合物6和化合物7a-f用生理盐水溶解,用于S180小鼠给药。在无菌环境中取接种于雄性ICR小鼠10天生长旺盛的S180腹水瘤液,用生理盐水稀释成(1:2)的液体充分混合,将肿瘤细胞悬液用新鲜配制的0.2%台盼蓝染色,混匀后按白细胞计数方法计数,染蓝色者为死细胞,不染色者为活细胞。按细胞浓度=4大方格内活细胞数/4×104×稀释倍数=细胞数/mL计算细胞密度,按细胞存活率=活细胞数/(活细胞数+死细胞数)×100%计算细胞存活率。将存活率大于90%的瘤液用匀浆法制成密度为2.0×107个/mL的细胞悬液。该细胞悬液接种于小鼠右腋皮下(0.2mL/只),制造S180荷瘤小鼠。接种24h后S180荷瘤小鼠每日腹腔注射阿霉素的生理盐水溶液(剂量为2μmol/kg/天g)或腹腔注射化合物6的生理盐水溶液(剂量为1μmol/kg/天)或腹腔注射化合物7a-f的生理盐水溶液(剂量为0.1μmol/kg/天),每组10只。每天给药一次,连续给药12天。最后一次给药的次日乙醚麻醉脱颈椎处死,然后用镊子固定小鼠右腋肿瘤生长部位,剪开皮肤钝性剥离肿瘤并称重。用瘤重(均值±SD g)表示疗效,数据用t检验和方差分析。结果见表1。在0.1μmol/kg剂量下化合物7a-f不仅有效地抑制肿瘤生长,而且活性与剂量比它们大10倍的化合物6没有显著性差异。这些数据表明,本发明有显著的技术效果。
表1化合物7a-f对S180小鼠肿瘤生长的影响
a)与生理盐水比p<0.01,与化合物6比p>0.05;n=10。
Claims (3)
2.权利要求1的1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-AA-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮的制备方法,该方法包括:
(1)制备6-(4-羟基-3-甲氧苯基)-5,6-己烯-2,4-二酮(1);
(2)制备2-(4-甲酰基-2-甲氧基苯氧基)-乙酸苄酯(2);
(3)以步骤(1)和步骤(2)的产物为反应原料制备1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(3);
(4)将1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮皂化,得到1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰乙酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(4);
(5)化合物4和L-茶氨酸苄酯偶联得到1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸苄酯基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(5);
(6)将化合物5皂化得到1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酸基-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮(6);
(7)化合物6和L-氨基酸苄酯偶联得到权利要求1的1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-AA-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮。
3.权利要求1的1-(4-羟基-3-甲氧基苯基)-7-(4-氧乙酰茶氨酰-AA-OBzl-3-甲氧基苯基)-1,6-庚二烯-3,5-二酮在制备抗肿瘤生长药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710457355.7A CN109134595B (zh) | 2017-06-16 | 2017-06-16 | 茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710457355.7A CN109134595B (zh) | 2017-06-16 | 2017-06-16 | 茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109134595A CN109134595A (zh) | 2019-01-04 |
CN109134595B true CN109134595B (zh) | 2022-02-08 |
Family
ID=64830482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710457355.7A Expired - Fee Related CN109134595B (zh) | 2017-06-16 | 2017-06-16 | 茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109134595B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111848729B (zh) * | 2019-04-30 | 2022-06-24 | 首都医科大学 | 茶氨酰四氢咪唑并吡啶-6-甲酰天冬酰胺和谷氨酰胺的制备,活性和应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009023357A2 (en) * | 2007-05-25 | 2009-02-19 | University Of Rochester | Curcumin derivatives and their use as radioprotectors |
WO2010033580A2 (en) * | 2008-09-19 | 2010-03-25 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Curcumin conjugates for treating and preventing cancers |
CN102241604A (zh) * | 2010-05-12 | 2011-11-16 | 首都医科大学 | 氨基酸修饰的姜黄素及其合成方法和应用 |
CN102503842A (zh) * | 2011-11-15 | 2012-06-20 | 江西东邦药业有限公司 | 一种姜黄素衍生物及其制备方法和用途 |
CN103450199A (zh) * | 2012-06-01 | 2013-12-18 | 首都医科大学 | 茶氨酸修饰的咔啉酰氨基酸苄酯、其制备、抗肿瘤活性和应用 |
CN103450335A (zh) * | 2012-06-01 | 2013-12-18 | 首都医科大学 | β-咔啉酰色氨酰色氨酰氨基酸苄酯、其合成、抗肿瘤作用及应用 |
CN103845325A (zh) * | 2012-12-06 | 2014-06-11 | 烟台大学 | 茶氨酸硝香酰胺在制备具有预防和治疗癌症等疾病的产品中的应用 |
-
2017
- 2017-06-16 CN CN201710457355.7A patent/CN109134595B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009023357A2 (en) * | 2007-05-25 | 2009-02-19 | University Of Rochester | Curcumin derivatives and their use as radioprotectors |
WO2010033580A2 (en) * | 2008-09-19 | 2010-03-25 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Curcumin conjugates for treating and preventing cancers |
CN102241604A (zh) * | 2010-05-12 | 2011-11-16 | 首都医科大学 | 氨基酸修饰的姜黄素及其合成方法和应用 |
CN102503842A (zh) * | 2011-11-15 | 2012-06-20 | 江西东邦药业有限公司 | 一种姜黄素衍生物及其制备方法和用途 |
CN103450199A (zh) * | 2012-06-01 | 2013-12-18 | 首都医科大学 | 茶氨酸修饰的咔啉酰氨基酸苄酯、其制备、抗肿瘤活性和应用 |
CN103450335A (zh) * | 2012-06-01 | 2013-12-18 | 首都医科大学 | β-咔啉酰色氨酰色氨酰氨基酸苄酯、其合成、抗肿瘤作用及应用 |
CN103845325A (zh) * | 2012-12-06 | 2014-06-11 | 烟台大学 | 茶氨酸硝香酰胺在制备具有预防和治疗癌症等疾病的产品中的应用 |
Non-Patent Citations (4)
Title |
---|
Cancer Stem Cells: Potential Target for Bioactive Food Components;Young S. Kim等;《J Nutr Biochem》;20120730;第23卷(第7期);691-698 * |
Design, synthesis and characterization of some bioactive conjugates of curcumin with glycine, glutamic acid, valine and demethylenated piperic acid and study of their antimicrobial and antiproliferative properties;Shiv K. Dubey等;《European Journal of Medicinal Chemistry》;20081231;1837-1846 * |
姜黄素化合物酯缩合前药及活性研究进展;王丽华等;《海峡药学》;20151231;第27卷(第6期);3-8 * |
姜黄素衍生物的合成及其抗肿瘤活性;司桂福等;《合肥师范学院学报》;20151130;第33卷(第6期);62-64 * |
Also Published As
Publication number | Publication date |
---|---|
CN109134595A (zh) | 2019-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109134596B (zh) | 茶氨酰氨基酸修饰的姜黄素,其合成,活性和应用 | |
CN109134598B (zh) | 茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 | |
CN109111501B (zh) | 脂肪氨基酸修饰的吲哚乙醇衍生物, 其合成,活性和应用 | |
CN109081801B (zh) | 酸性氨基酸修饰的吲哚乙醇衍生物,其合成,活性和应用 | |
CN109081803B (zh) | 极性氨基酸修饰的吲哚乙醇衍生物,其合成,活性和应用 | |
CN109134595B (zh) | 茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 | |
CN108929320B (zh) | 3r-吲哚甲基-6r-恶唑烷酮修饰的哌嗪-2,5-二酮,其合成,活性和应用 | |
CN109134597B (zh) | 茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 | |
CN108948137B (zh) | 3s-吲哚乙基-6s-极性氨基酸修饰的哌嗪-2,5-二酮,其合成,活性和应用 | |
CN109111500B (zh) | 茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 | |
CN110577518B (zh) | 甲基吲哚和酰胺侧链氨基酸修饰的二酮哌嗪,其合成及应用 | |
CN110577568B (zh) | 甲基吲哚和酰胺侧链氨基酸修饰的二酮哌嗪,其合成,活性和应用 | |
CN110551121A (zh) | 谷氨酰胺酰氨基正己酰咔啉羧酸苄酯,其制备,活性和应用 | |
CN108929369B (zh) | 3r-吲哚甲基-6r-酸性氨基酸修饰的哌嗪-2,5-二酮,其合成,活性和应用 | |
CN110551175B (zh) | 氨基酸和氨甲环酸修饰的二酮哌嗪,其制备,活性及应用 | |
CN112110987B (zh) | 天冬胺酰茶氨酸苯丙氨酸修饰的5-氟尿嘧啶,其合成,活性和应用 | |
CN108947979B (zh) | 3r-吲哚甲基-6r-极性氨基酸修饰的哌嗪-2,5-二酮,其合成,活性和应用 | |
CN112300245B (zh) | Rgds和茶氨酸共同修饰的5-氟尿嘧啶,其合成,活性和应用 | |
CN108976279B (zh) | 茶氨酰氨基酸苄酯修饰的姜黄素,其合成,活性和应用 | |
CN109081802B (zh) | 碱性氨基酸修饰的吲哚乙醇衍生物,其合成,活性和应用 | |
CN110577517B (zh) | 甲基吲哚和芳香氨基酸修饰的2,5-二酮哌嗪,其合成,活性和应用 | |
CN109111390B (zh) | Met修饰的吲哚乙醇衍生物,其合成,活性和应用 | |
CN108947978B (zh) | 3R-吲哚甲基-6R-Tyr修饰的哌嗪-2,5-二酮,其合成,活性和应用 | |
CN108929313B (zh) | 3r-吲哚甲基-6r-脂肪氨基酸修饰的哌嗪-2,5-二酮,其合成,活性和应用 | |
CN109456311B (zh) | 3r-吲哚甲基-6r-芳香氨基酸修饰的哌嗪-2,5-二酮,其合成,活性和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220208 |